Tecovirimat distribution reported during Los Angeles County mpox outbreak

Photo by Cht Gsml / Unsplash

CDC MMWR Published April 4, 2026 Medically reviewed April 20, 2026 By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Note: This is a descriptive report, not a clinical study of tecovirimat effectiveness.

A public health report describes the distribution of tecovirimat during the 2022-23 mpox outbreak in Los Angeles County. The report does not specify the study design, sample size, or comparator group. It provides no data on clinical outcomes, treatment effectiveness, or patient follow-up.

No results regarding the impact of tecovirimat on disease severity, duration, or transmission are presented. The safety and tolerability profile of the distributed medication was not reported, with adverse events, serious adverse events, and discontinuation rates all listed as 'not reported'.

Key limitations include the absence of a formal study design, outcome measures, and any comparative analysis. The funding sources and potential conflicts of interest were also not reported. This document serves as a descriptive account of public health activity rather than a source of clinical evidence.

Its practice relevance is minimal for informing treatment decisions. Clinicians should recognize this as an administrative report, not a clinical study, and rely on more rigorous evidence when considering tecovirimat use for mpox.